A Randomized, 4-Period, 4-Sequence, Double-Blind, Crossover Design Study to Assess the Effect of Single Doses of TAK-438 40 mg, TAK-438 120 mg, Placebo and Positive Control Moxifloxacin (Open-Label) on the QTc Interval in Healthy Adult Subjects

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.